July 31, 2026

Lung Cancer Care in 2026: Earlier Detection, Earlier Intervention, More Individualized Treatment

Lung cancer care is entering a more precise and increasingly proactive era. While the disease remains a leading cause of cancer mortality, earlier detection through low-dose CT screening, broader use of molecular profiling and rapid advances in targeted therapy and immunotherapy are changing how patients are diagnosed, staged and treated.

Baptist Health South Florida

July 16, 2026

Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC

As reported in The Lancet by Lu et al, an interim analysis of the Chinese phase III HARMONi-6 trial showed that ivonescimab plus chemotherapy was associated with significantly improved overall surviva...

The ASCO Post

July 14, 2026

Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC

The phase III LIBRETTO-432 trial of adjuvant therapy with the central nervous system (CNS)–penetrant oral RET inhibitor selpercatinib met its primary endpoint of improved event-free survival in patien...

The ASCO Post

July 14, 2026

Aumolertinib Plus Chemotherapy in EGFR-Mutated Advanced NSCLC

In a Chinese phase III trial (AENEAS2) reported in The Lancet Oncology, Li et al found that the combination of aumolertinib with chemotherapy significantly improved progression-free survival vs aumole...

The ASCO Post

July 06, 2026

Performance of Lung Cancer Risk Prediction Models Across Racial and Ethnic Groups in the United States

Researchers assessed the performance of 16 lung cancer risk models in nearly 642,000 Asian, Hispanic, non-Hispanic Black, and non-Hispanic White adults aged 50 to 80 years with a history of smoking.

The ASCO Post

July 06, 2026

Performance of Lung Cancer Risk Prediction Models Across Racial and Ethnic Groups in the United States

Researchers assessed the performance of 16 lung cancer risk models in nearly 642,000 Asian, Hispanic, non-Hispanic Black, and non-Hispanic White adults aged 50 to 80 years with a history of smoking.

The ASCO Post

July 01, 2026

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

Dana-Farber

July 01, 2026

New AI-Enabled Technology Supports Radiology Follow-Up Throughout Baptist Health

Baptist Health Herbert Wertheim Cancer Institute has launched Eon, an AI-enabled software platform that analyzes radiology reports and helps identify and prioritize incidental findings for clinical review, in an effort to support timely, coordinated patient care.

Baptist Health South Florida

June 25, 2026

The importance of robust genomic testing for patients

Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.

UCI Health

June 22, 2026

A Burning Question: Can Wildfire Smoke Drive Cancer Risk?

Exposure to wildfire smoke was associated with significantly elevated risks of several cancers, including lung, colorectal, breast, bladder, and blood cancers, according to evidence from the Prostate,...

The ASCO Post